fasudil has been researched along with Angina Pectoris in 11 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Angina Pectoris: The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The coronary diameter at the concentric stenotic site, which is considered to reflect the whole circumferential atherosclerosis, in patients with stable angina pectoris (SAP; n=11) and the control site in patients with SAP and chest pain syndrome (CPS; n=9), was measured at baseline and after the intracoronary administration of nitroglycerin (200 microg) and the subsequent intravenous infusion of fasudil (30 mg for 30 min), a Rho-kinase inhibitor, during coronary angiography." | 9.12 | Vasodilatory effect of subsequent administration of fasudil, a rho-kinase inhibitor, surpasses that of nitroglycerin at the concentric coronary stenosis in patients with stable angina pectoris. ( Atarashi, H; Ibuki, C; Ishii, K; Kishida, H; Kodani, E; Otsuka, T; Suzuki, T; Takano, T, 2006) |
| "The coronary diameter at the concentric stenotic site, which is considered to reflect the whole circumferential atherosclerosis, in patients with stable angina pectoris (SAP; n=11) and the control site in patients with SAP and chest pain syndrome (CPS; n=9), was measured at baseline and after the intracoronary administration of nitroglycerin (200 microg) and the subsequent intravenous infusion of fasudil (30 mg for 30 min), a Rho-kinase inhibitor, during coronary angiography." | 5.12 | Vasodilatory effect of subsequent administration of fasudil, a rho-kinase inhibitor, surpasses that of nitroglycerin at the concentric coronary stenosis in patients with stable angina pectoris. ( Atarashi, H; Ibuki, C; Ishii, K; Kishida, H; Kodani, E; Otsuka, T; Suzuki, T; Takano, T, 2006) |
| "We studied the antiischemic properties of fasudil, a Rho-kinase inhibitor, in conscious rabbits with coronary vasospasm induced by vasopressin and endothelin." | 3.71 | Antiischemic properties of fasudil in experimental models of vasospastic angina. ( Asano, T; Ikegaki, I; Sato, S; Shimokawa, H, 2001) |
| "Epicardial coronary stenosis causes myocardial ischemia; however, the role of coronary microvessels is poorly understood in the pathogenesis of effort angina." | 2.73 | Anti-ischemic effects of fasudil, a specific Rho-kinase inhibitor, in patients with stable effort angina. ( Fukumoto, Y; Hirakawa, Y; Hirooka, Y; Inokuchi, K; Ito, A; Masumoto, A; Mohri, M; Shimokawa, H; Takeshita, A, 2007) |
| "The fasudil treatment significantly prolonged the maximum exercise time and the time to the onset of 1-mm ST segment depression on treadmill exercise test (both p < 0." | 2.70 | Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. ( Hiramori, K; Hosoda, S; Iinuma, H; Katagiri, T; Kato, K; Kishida, H; Minamino, T; Nakashima, M; Osada, H; Shimokawa, H; Yamauchi, K; Yui, Y, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (90.91) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Suda, A | 1 |
| Takahashi, J | 1 |
| Hao, K | 1 |
| Kikuchi, Y | 1 |
| Shindo, T | 1 |
| Ikeda, S | 1 |
| Sato, K | 1 |
| Sugisawa, J | 1 |
| Matsumoto, Y | 1 |
| Miyata, S | 1 |
| Sakata, Y | 1 |
| Shimokawa, H | 5 |
| Jawad, E | 1 |
| Arora, R | 1 |
| Hiramori, K | 1 |
| Iinuma, H | 1 |
| Hosoda, S | 1 |
| Kishida, H | 3 |
| Osada, H | 1 |
| Katagiri, T | 1 |
| Yamauchi, K | 1 |
| Yui, Y | 1 |
| Minamino, T | 1 |
| Nakashima, M | 1 |
| Kato, K | 1 |
| Nakayama, M | 1 |
| Amano, M | 1 |
| Kawabata, S | 1 |
| Kaibuchi, K | 1 |
| Takefuji, M | 1 |
| Vicari, RM | 1 |
| Chaitman, B | 1 |
| Keefe, D | 1 |
| Smith, WB | 1 |
| Chrysant, SG | 1 |
| Tonkon, MJ | 1 |
| Bittar, N | 1 |
| Weiss, RJ | 1 |
| Morales-Ballejo, H | 1 |
| Thadani, U | 1 |
| Otsuka, T | 2 |
| Ibuki, C | 2 |
| Suzuki, T | 2 |
| Ishii, K | 2 |
| Kodani, E | 2 |
| Atarashi, H | 2 |
| Takano, T | 2 |
| Fukumoto, Y | 1 |
| Mohri, M | 1 |
| Inokuchi, K | 1 |
| Ito, A | 1 |
| Hirakawa, Y | 1 |
| Masumoto, A | 1 |
| Hirooka, Y | 1 |
| Takeshita, A | 1 |
| Hikita, H | 1 |
| Sato, A | 1 |
| Yoshida, H | 1 |
| Kusama, Y | 1 |
| Mizuno, K | 1 |
| Sato, S | 1 |
| Ikegaki, I | 2 |
| Asano, T | 2 |
| Utsunomiya, T | 1 |
| Satoh, S | 1 |
| Toshima, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs. Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation[NCT02338232] | 32 participants (Actual) | Interventional | 2015-07-07 | Terminated (stopped due to Lack of Accrual) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for fasudil and Angina Pectoris
| Article | Year |
|---|---|
Chronic stable angina pectoris.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acetanilides; Angina Pectoris; Antihypertensive Agent | 2008 |
[Involvement of small GTPase Rho and Rho-kinase in the pathogenesis of hypertension and hypertensive target organ damage].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Angina Pectoris; Animals; Arteriosclerosis; C | 2004 |
[Exercise-induced vasospastic angina].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angina Pectoris; Calcium Channel Blockers; Diagnosis, | 2007 |
5 trials available for fasudil and Angina Pectoris
| Article | Year |
|---|---|
Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Aged, 80 and over; Angina Pectoris; Enzy | 2002 |
Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Angina Pectoris; Double-Blind Method; Female; H | 2005 |
Vasodilatory effect of subsequent administration of fasudil, a rho-kinase inhibitor, surpasses that of nitroglycerin at the concentric coronary stenosis in patients with stable angina pectoris.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Angina Pectoris; Angiography; Chest Pain; Coron | 2006 |
Anti-ischemic effects of fasudil, a specific Rho-kinase inhibitor, in patients with stable effort angina.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Angina Pectoris; Cardiac Pacing, Artificial; Co | 2007 |
Administration of the Rho-kinase inhibitor, fasudil, following nitroglycerin additionally dilates the site of coronary spasm in patients with vasospastic angina.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Angina Pectoris; Coronary Angiography; Coronary | 2008 |
3 other studies available for fasudil and Angina Pectoris
| Article | Year |
|---|---|
Coronary Functional Abnormalities in Patients With Angina and Nonobstructive Coronary Artery Disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Angina Pectoris; Coronary Angiography; Coronary | 2019 |
Antiischemic properties of fasudil in experimental models of vasospastic angina.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angina Pectoris; Animals; Coronary Vasospasm; Disease | 2001 |
Antianginal effects of hydroxyfasudil, a Rho-kinase inhibitor, in a canine model of effort angina.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Anesthesia; Angina Pectoris; Animals; Cardiac Pacing, | 2001 |